NCI-2024-06076

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy And Safety of Divarasib versus Sotorasib or Adagrasib In Patients with Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

This research study is a large clinical trial designed to test a new treatment for people with advanced lung cancer that has a specific gene mutation (called KRAS G12C). The patients in this trial have already been treated with other therapies, but their cancer is still active. KRAS G12C is a mutation that makes lung cancer harder to treat. Researchers are testing Divarasib to see if it can help people with this mutation live longer or feel better compared to current treatment options.

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06497556

Clinical Trial Site: Sinai/Columbia

To see all available clinical trials click here.